Table 2. Proportion of Medication-Adherent Union Members, from Baseline to the End of the Study, by Primary Care Provider Participation in the Primary Care Information Project

Medication Type	Patients (n)	Baseline		Adherent Members at the End of the Study (%)^*	Change (End of Study − Baseline)^†
Medication Type	Patients (n)	MPR (%)	Adherent Members (%)^*	Adherent Members at the End of the Study (%)^*	Change (End of Study − Baseline)^†
Diabetes (only)
Diabetes-specific^‡
Non-PCIP	205	79.01	26.07	27.94	+1.87
PCIP	63	69.70	18.52	31.76	+13.24
Lipid-controlling^{^§}
Non-PCIP	129	76.67	16.63	13.24	−3.39
PCIP	40	65.32	11.11	16.47	+5.36
Hypertension (only)
Hypertension-specific^†
Non-PCIP	2652	79.37	33.75	37.88	+4.13
PCIP	735	77.61	32.89	37.25	+4.36
Lipid-controlling^§
Non-PCIP	1198	77.63	14.59	17.05	+2.46
PCIP	295	76.47	12.62	13.51	+0.89
Comorbid diabetes and hypertension
Diabetes-specific^‡
Non-PCIP	1322	79.67	37.37	37.87	+0.50
PCIP	357	76.63	36.04	37.10	+1.06
Hypertension-specific^‖
Non-PCIP	1533	79.52	44.44	47.76	+3.32
PCIP	390	77.39	40.57	41.94	+1.37
Lipid-controlling^§
Non-PCIP	1045	78.55	29.25	31.29	+2.04
PCIP	250	75.46	24.34	28.23	+3.89

↵* The proportion of members with a medication possession ratio (MPR) ≥80%.
↵† Change in the proportion of members with an MPR ≥80% from baseline (2008) to the end of the study (2011).
↵‡ Diabetes therapeutic drug classes include biguanides, sulfonylureas, thiazolidinediones, insulins, and dipeptidyl peptidase IV inhibitors.
↵§ Lipid-controlling therapeutic drug classes include HMG-CoA reductase inhibitors and fibric acid derivatives.
↵‖ Hypertension therapeutic drug classes include angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, β-adrenergic blocking agents, calcium channel blocking agents (dihydropyridines), phosphodiesterase inhibitors, thiazide diruetics.
PCIP, Primary Care Information Project.